Article

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

2015-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 406d5423-1922-53a2-aa23-a5144d20d208
DOI: 10.1016/s0959-8049(16)31724-5

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studiesDOI 10.1016/s0959-8049(16)31724-5Read

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read

AZD3759 for CNS metastases in EGFR-mutant lung cancer.Semantic proximity Read

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Semantic proximity Read

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.Semantic proximity Read

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case SeriesSemantic proximity Read

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvementSemantic proximity Read

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignSemantic proximity Read

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)Semantic proximity Read

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.Semantic proximity Read

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)Semantic proximity Read

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studySemantic proximity Read